In the context of dual antagonists, bosentan, a compound that concurrently targets both endothelin receptor type A (ETAR) and ETBR, has been approved for addressing pulmonary hypertension [263]. The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.